## DOC: Healthpeak Properties, Inc. - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 4.08 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($15.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Alexandria Real Estate Equities: How a Science-Centric REIT Became a Critical Piece of the Innovation Economy**
- Source: AD HOC NEWS | 20260103T001009 | Somewhat-Bullish | Relevance: 72%
- Alexandria Real Estate Equities has specialized in building science-centric lab and R&D campuses, transforming lab space into a high-tech platform for the life science, agtech, and advanced technology ecosystems. The company's strategy involves creating innovation campuses in key R&D clusters with integrated infrastructure, amenities, venture capital, and a focus on ESG, giving it a defensible edge over traditional real estate rivals. This specialized product positions Alexandria as a critical infrastructure provider for the innovation economy, driving its valuation and growth prospects within the REIT sector.

**2. Sabra Healthcare REIT (NASDAQ:SBRA) Upgraded at Wall Street Zen**
- Source: MarketBeat | 20260103T091009 | Neutral | Relevance: 64%
- Wall Street Zen has upgraded Sabra Healthcare REIT (NASDAQ:SBRA) from a "sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy." Sabra exceeded quarterly EPS expectations and saw a 6.7% revenue increase year-over-year, setting positive FY2025 EPS guidance. The company exhibits high institutional ownership, with approximately 99.40% of shares held by such investors.

**3. Alexandria Real Estate Equities: How a Science-Centric REIT Became a Critical Piece of the Innovatio**
- Source: AD HOC NEWS | 20260103T010457 | Neutral | Relevance: 64%
- Alexandria Real Estate Equities (ARE) has successfully transformed lab space into a specialized, high-tech product, building mission-critical life science campuses that function as innovation platforms rather than traditional real estate. The company addresses the complex infrastructure needs of cutting-edge research, creating purpose-built environments in key R&D clusters that integrate venture capital, strategic partnerships, and community-driven amenities. This specialized approach, coupled with strong ESG integration and a powerful brand, provides ARE with a significant competitive advantage over more diversified real estate firms, positioning it as a fundamental component of the global innovation economy.

**4. MPW stock ends higher to start 2026 as investors watch rates and Medical Properties Trustâ€™s dividend**
- Source: ts2.tech | 20260103T230900 | Neutral | Relevance: 61%
- Medical Properties Trust (MPW) shares rose 1.6% to $5.08 on Friday, January 3, 2026, as U.S. stocks opened the year higher despite firming Treasury yields. Investors are closely monitoring upcoming jobs and inflation data due to the REIT's sensitivity to interest rates, especially ahead of its January 8 dividend payment. The stock, a high-yield REIT, remains a focus for traders seeking income names, trading well above its 52-week low but below its high, with an annualized dividend yield of roughly 7%.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Jefferies | $17 | $21 | -19% |
| 2025-12-15 | Evercore ISI Gr | $21 | $22 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Jefferies | down | Hold |
| 2025-12-15 | Evercore ISI Gr | main | Outperform |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 15.7% (-1.9%)
- Blackrock Inc.: 10.5% (-1.7%)
- JPMORGAN CHASE & CO: 8.1% (+182.0%)
- State Street Corpora: 7.1% (+1.8%)
- Principal Financial : 3.9% (-3.2%)

### Key Risks

1. Valuation risk: PEG 4.1x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 8.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_10 improving +3.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.08 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.4B |
| Beta | 1.10 |
| 52W Range | $15.71 - $21.28 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.08 |
| Forward P/E | 65.6 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -1.3% to 2.1% (+3.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 45. OFD pattern: +SUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.11% (CS: 68) | Neutral |
| RSI_14 | 44.8 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 0.952x | Below |
| vs SMA200 | 0.919x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $16.41
- **Stop Loss:** $15.77 (3.9% risk)
- **Target:** $17.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1796
- **Position Value:** $29,472.36
- **Portfolio %:** 29.47%
- **Risk Dollars:** $1,150.00
- **Risk Per Trade:** 1.15%
- **Modifiers:** L1 115% | L2 100% | Combined 1.15x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-05 (Est: $0.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.06 | $-0.18 | -403.2% |
| 2025Q2 | $0.06 | $0.06 | +12.2% |
| 2025Q1 | $0.04 | $0.06 | +40.7% |
| 2024Q4 | $0.05 | $0.05 | -4.7% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*